2005 TRIPS amendment on public health (Article 31bis)

E616453

The 2005 TRIPS amendment on public health (Article 31bis) is a World Trade Organization rule change that allows countries to export patented medicines made under compulsory licenses to nations lacking sufficient pharmaceutical manufacturing capacity, in order to improve access to essential drugs.

Try in SPARQL Jump to: Surface forms Statements Referenced by

All labels observed (1)

Statements (47)

Predicate Object
instanceOf TRIPS Agreement amendment
World Trade Organization rule change
international intellectual property law instrument
addresses public health problems affecting developing and least-developed countries
adoptedBy World Trade Organization General Council NERFINISHED
adoptionDate 2005-12-06
allows export of patented medicines produced under compulsory licences
regional trade agreements of developing or least-developed countries to use the system jointly
alsoKnownAs Article 31bis of the TRIPS Agreement NERFINISHED
TRIPS public health amendment NERFINISHED
appliesTo WTO member states NERFINISHED
beneficiariesInclude least-developed country WTO members
other WTO members with insufficient or no pharmaceutical manufacturing capacity
concerns access to medicines in developing countries
compulsory licensing of pharmaceutical patents
createsExceptionTo requirement that production under compulsory licence be predominantly for the supply of the domestic market
criticizedFor complex procedural requirements
limited practical use by WTO members
designedTo balance patent protection with public health needs
enteredIntoForce 2017-01-23
entryIntoForceCondition acceptance by two-thirds of WTO members
field global public health policy
intellectual property law
international trade law
implementedBy Annex to the TRIPS Agreement on the implementation of Article 31bis NERFINISHED
influenced national legislation on compulsory licensing for export in several WTO members
legalBasisFor export of pharmaceutical products made under compulsory licence
legalForm amendment to Annex 1C of the WTO Agreement
linkedTo Doha Declaration on the TRIPS Agreement and Public Health NERFINISHED
modifies Article 31 of the TRIPS Agreement
originatesFrom 2003 WTO General Council Decision on the Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health NERFINISHED
partOf Agreement on Trade-Related Aspects of Intellectual Property Rights NERFINISHED
World Trade Organization legal framework
permits importation of generics produced under compulsory licence from other WTO members
purpose to implement the 2001 Doha Declaration on the TRIPS Agreement and Public Health
to improve access to essential medicines in countries with insufficient or no pharmaceutical manufacturing capacity
replaces 2003 WTO waiver on exports of medicines under compulsory licence
requires measures to prevent re-exportation of products supplied under the system
notification to the WTO by exporting members granting compulsory licences under the system
notification to the WTO by importing members using the system
publication of information about quantities and destinations of products supplied under the system
remuneration to patent holders by exporting members granting compulsory licences
special labelling or marking of products supplied under the system
scope pharmaceutical products needed to address public health problems
subjectOf WTO notifications by importing and exporting members
debates on access to medicines and intellectual property
interpretative discussions in the WTO TRIPS Council

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Doha Declaration on the TRIPS Agreement and Public Health influenced 2005 TRIPS amendment on public health (Article 31bis)